311 related articles for article (PubMed ID: 34688813)
21. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
22. Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation.
Zhang T; Liu Y; Zeng R; Ling Q; Wen P; Fan J; Peng Z
Liver Int; 2018 Apr; 38(4):724-732. PubMed ID: 28941036
[TBL] [Abstract][Full Text] [Related]
23. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.
Liu MZ; He HY; Zhang YL; Hu YF; He FZ; Luo JQ; Luo ZY; Chen XP; Liu ZQ; Zhou HH; Shao MJ; Ming YZ; Xin HW; Zhang W
Acta Pharmacol Sin; 2017 Mar; 38(3):415-423. PubMed ID: 28112181
[TBL] [Abstract][Full Text] [Related]
24. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
27. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
28. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
Wanas H; Kamel MH; William EA; Fayad T; Abdelfattah ME; Elbadawy HM; Mikhael ES
J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients.
Tang J; Xu J; Zhang YL; Liu R; Liu MZ; Hu YF; Shao MJ; Zhu LJ; Cao S; Xin HW; Feng GW; Shang WJ; Meng XG; Zhang LR; Ming YZ; Zhang W; Zhou G
J Clin Pharmacol; 2019 Jun; 59(6):890-899. PubMed ID: 30861159
[TBL] [Abstract][Full Text] [Related]
30. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
31. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
32. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
33. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
[TBL] [Abstract][Full Text] [Related]
34. Impact of single-nucleotide polymorphisms on tacrolimus pharmacokinetics in liver transplant patients after switching to once-daily dosing.
Park J; Lee KW; Oh SC; Park MY; Lee JM; Hong SY; Hong SK; Choi Y; Yi NJ; Suh KS
Hepatol Int; 2023 Feb; 17(1):262-270. PubMed ID: 35972639
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
[TBL] [Abstract][Full Text] [Related]
36. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.
Li CJ; Li L; Lin L; Jiang HX; Zhong ZY; Li WM; Zhang YJ; Zheng P; Tan XH; Zhou L
PLoS One; 2014; 9(1):e86206. PubMed ID: 24465960
[TBL] [Abstract][Full Text] [Related]
37. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
Li JL; Liu S; Fu Q; Zhang Y; Wang XD; Liu XM; Liu LS; Wang CX; Huang M
Pharmacogenomics; 2015; 16(12):1355-65. PubMed ID: 26228923
[TBL] [Abstract][Full Text] [Related]
38. TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period.
Ou B; Liu Y; Zhang T; Sun Y; Chen J; Peng Z
Pharmacotherapy; 2019 Jan; 39(1):67-76. PubMed ID: 30537010
[TBL] [Abstract][Full Text] [Related]
39. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
